Given the increasing evidence for an acquired CFTR dysfunction not only during HF but also in classic chronic lung diseases such as COPD and asthma (35), the indication that CFTR modulators may be useful therapeutics in the treatment of acquired CFTR abnormalities is certainly of interest to the field. This evidence concerns the gene CFTR and asthma.